市場調査レポート

商品コード

972331

CART細胞治療薬の世界市場 (2020-2030年)：製品・機序・用途・標的抗原・国別分析・競合情勢

Global CAR T-Cell Therapy Market: Focus on Product, Mechanism, Application, Target Antigen, Country Data (14 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030

出版日: 2020年11月23日 | 発行:

BIS Research Inc. | ページ情報: 英文 266 Pages | 納期: 即日から翌営業日

価格

PDF (Single User License)

USD 5,000 523,850円

レポートPDFを1名様のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストが可能です。PDFの印刷は可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Site License)

USD 6,500 681,005円

レポートPDFを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストが可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF and Excel (Global License)

USD 8,000 838,160円

レポートPDFを同一企業の全世界の方にご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストが可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。付属のExcelには、PDF内で使用されている数値データが含まれます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=104.77円

全表示
概要
図表
目次

概要

比較する

世界のCART細胞治療薬の市場規模は予測期間中44.79%のCAGRで成長すると予測されています。老齢人口の増加、リンパ腫および白血病の症例数の増加、化学療法や放射線療法などの代替療法では奏効しない再発・難治性の癌症例の増加、新規免疫療法のR&Dへの注力、強力な製品パイプラインなどの要因が同市場の成長を推進しています。

当レポートでは、世界のCART細胞治療薬の市場を調査し、市場および技術の定義・概要、現在の上市済み薬およびパイプライン薬のプロファイル、特許情勢、法的枠組み、新型コロナウイルス感染症 (COVID-19) およびその他の市場影響因子の分析、市場規模の推移・予測、適応症・標的抗原・地域/主要国など各種区分別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

エグゼクティブサマリー

第1章技術の定義

第2章調査範囲

第3章調査手法

第4章市場概要

開発タイムライン
市場成長の可能性
臨床試験

第5章世界市場の規模・予測

上市済み薬
- Tisagenlecleucel (Kymriah）
- Axicabtagene Ciloleucel（Yescarta）
- Brexucabtagene Autoleucel（Tecartus）
パイプライン薬
- BB2121（Idecaptagene Cicleucel）
- JCAR017（Lisocabtagene Maraleucel）
- KTE-C19（Axicabtagene Ciloleucel）
- CTL019（Tisagenlecleucel）
- JNJ-68284528
COVID-19の影響

第6章特許情勢

第7章 CART細胞治療薬：疫学

概要
副作用
副作用の管理

第8章産業考察

概要
関連規制シナリオ
法的要件・枠組み：米国
法的要件・枠組み：欧州
法的要件・枠組み：アジア太平洋
世界の迅速指定
薬価
償還

第9章 CART細胞治療薬の開発・製造

概要
CART細胞治療薬の課題
- 治療薬の承認
- 製造品質管理
- 有効性と質調整生存年（QALY）評価
- 安全性評価
- 価格・患者アクセス
- 償還

第10章市場力学

影響分析
市場成長推進因子
市場成長抑制因子
市場機会

第11章市場分析・予測：用途別

概要
びまん性大細胞型B細胞リンパ腫（DLBCL）
急性リンパ芽球性白血病（ALL）
多発性骨髄腫（MM）
慢性リンパ性白血病（CLL）
濾胞性リンパ腫（FL）
マントル細胞リンパ腫（MCL）
その他

第12章市場分析・予測：標的抗原別

概要
CD19/CD22
BCMA（B細胞成熟抗原）
その他

第13章市場分析・予測：地域・主要国別

北米
- 米国
- カナダ
欧州
- ドイツ
- 英国
- フランス
- イタリア
- スペイン
- その他
アジア太平洋
- 中国
- 日本
- インド
- 韓国
- オーストラリア
- その他
ラテンアメリカ
- ブラジル
- メキシコ
- その他
その他の地域

第14章競合情勢

主な展開・戦略
市場シェア分析

第15章企業プロファイル

Amgen, Inc.
Autolus Therapeutics plc
Bellicum Pharmaceuticals, Inc.
Bluebird Bio Inc
Bristol-Myers Squibb Company
CARsgen Therapeutics, Ltd.
Cartesian Therapeutics, Inc.
Cellectis S.A.
Celyad Oncology SA
Fortress Biotech, Inc
Janssen Pharmaceuticals, Inc.
Kite Pharma, Inc (A Gilead Company)
Legend Biotech Corporation
Novartis AG
Pfizer Inc.

図表

List of Tables

Table 1: Leading Players in Global CAR T-Cell Therapy Market
Table 8.1: History of Regulatory Activities and Tools Applied to Kymriah in U.S. and EU
Table 8.2: History of Regulatory Activities and Tools Applied to Yescarta in U.S. and EU
Table 8.3: Expedited Regulatory Designations Around the World
Table 10.1: Cytokine Release Syndrome (CRS) Grading Systems
Table 15.1: Amgen, Inc.: Pipeline Product Portfolio
Table 15.2: Autolus Therapeutics plc: Pipeline Product Portfolio
Table 15.3: Bellicum Pharmaceuticals, Inc.: Pipeline Product Portfolio
Table 15.4: Bluebird Bio Inc Company: Pipeline Product Portfolio
Table 15.5: Bristol Myers Squibb Company: Pipeline Product Portfolio
Table 15.6: CARsgen Therapeutics, Ltd Company: Pipeline Product Portfolio
Table 15.7: Cartesian Therapeutics, Inc.: Pipeline Product Portfolio
Table 15.8: Celyad Oncology SA Company: Pipeline Product Portfolio
Table 15.9: Fortress Biotech, Inc: Pipeline Product Portfolio
Table 15.10: Janssen Pharmaceuticals, Inc Company: Pipeline Product Portfolio
Table 15.11: Kite Pharma, Inc: Pipeline Product Portfolio
Table 15.12: Legend Biotech Corporation, Company: Pipeline Product Portfolio
Table 15.13: Novartis AG: Pipeline Product Portfolio
Table 15.14: Pfizer Plc: Pipeline Product Portfolio

List of Figures

Figure 1: Global Prevalence of Hematologic Malignancies, 2018
Figure 2: Global Geriatric Population (by Age)
Figure 3: Global CAR T-Cell Therapy Clinical Trials (by Region)
Figure 4: Global CAR T-Cell Therapy Market
Figure 5: Global CAR T-Cell Therapy: Impact Analysis
Figure 6: Share of Key Developments and Strategies, June 2015-June 2020
Figure 7: Global CAR T-Cell Therapy Market (by Application), 2019 and 2030
Figure 8: Global CAR T-Cell Therapy Market (by Target Antigen), 2019 and 2030
Figure 9: Global CAR T-Cell Therapy Market (by Region), 2019 and 2030
Figure 2.1: Global CAR T-Cell Therapy Market Segmentation
Figure 3.1: Global CAR T-Cell Therapy Market Methodology
Figure 3.2: Primary Research Methodology
Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
Figure 4.1: Timeline of CAR T-Cell Therapy Development (Year-Wise Analysis)
Figure 4.2: CAR T-Cell Therapy Market Revenue (by Region), 2019 and 2030
Figure 4.3: Global CAR T-Cell Therapy Clinical Trials (by Region)
Figure 4.4: Top 10 Target Antigens in CAR T-Cell Therapy Clinical Trials - U.S.
Figure 4.5: Global CAR T-Cell Therapy Clinical Trials (by Phase)
Figure 4.6: Top 10 Target Antigens in CAR T-Cell Therapy Clinical Trials - China
Figure 4.7: CAR T-Cell Therapy Clinical Trials in China (by Region)
Figure 4.8: CAR T-Cell Therapy Clinical Trials (by Phase)
Figure 4.9: CAR T-Cell Therapy Clinical Trials - Rest-of-the-World (by Phase)
Figure 4.10: Global CAR T-Cell Therapy Clinical Trials (by Phase)
Figure 5.1: Global CAR T-Cell Therapy Market (Kymriah - Product Revenue), 2019-2030
Figure 5.2: Global CAR T-Cell Therapy Market (Yescarta - Product Revenue), 2019-2030
Figure 5.3: Global CAR T-Cell Therapy Market (Tecartus - Product Revenue), 2020-2030
Figure 5.4: Global CAR T-Cell Therapy Market (Idecaptagene Cicleucel - Product Revenue)
Figure 5.5: Global CAR T-Cell Therapy Market (Lisocabtagene Maraleucel - Product Revenue)
Figure 5.6: Global CAR T-Cell Therapy Market (Axicabtagene Ciloleucel - Product Revenue)
Figure 5.7: Global CAR T-Cell Therapy Market (Tisagenlecleucel - Product Revenue)
Figure 5.8: Global CAR T-Cell Therapy Market (JNJ-68284528 - Product Revenue)
Figure 5.9: COVID-19 Status Globally
Figure 5.10: COVID-19 Progression Curve
Figure 5.11: Most Impacted Practices in CAR T-Cell Therapy
Figure 5.12: COVID-19 Impact on the CAR T-Cell Therapy Market
Figure 5.13: Impact of COVID-19 on Clinical Trials
Figure 5.14: Status of Clinical Trials
Figure 5.15: Disrupted Clinical Trials by Phase of Clinical Trial
Figure 5.16: Disrupted Clinical Trials by Therapy Area
Figure 5.17: Major Areas of Disruption
Figure 5.18: Diagnosis Rates of Various Cancer During Pandemic
Figure 5.19: Key Areas of Disruption in Commercial Operations
Figure 6.1: CAR T-Cell Therapy Patent Activity Ratio (by Region)
Figure 6.2: CAR T-Cell Therapy Patents (by Jurisdictions)
Figure 6.3: U.S. Patent Activity: Chimeric Antigen Receptor (Patents by Year)
Figure 7.1: Global Prevalence of Hematologic Malignancies , 2018
Figure 7.2: Estimated Incident Cases of Hematologic Malignancies in the U.S. (Total Population)
Figure 7.3: Estimated Incident Cases of Hematologic Malignancies in Canada (Total Population)
Figure 7.4: Estimated Incident Cases of Hematologic Malignancies in Germany (Total Population)
Figure 7.5: Estimated Incident Cases of Hematologic Malignancies in France (Total Population)
Figure 7.6: Estimated Incident Cases of Hematologic Malignancies in Italy (Total Population)
Figure 7.7: Estimated Incident Cases of Hematologic Malignancies in Spain (Total Population)
Figure 7.8: Estimated Incident Cases of Hematologic Malignancies in the U.K. (Total Population)
Figure 7.9: Estimated Incident Cases of Hematologic Malignancies in Japan (Total Population)
Figure 7.10: Estimated Incident Cases of Hematologic Malignancies in Australia (Total Population)
Figure 7.11: Grading System for Management of CAT T-Cell Toxicities
Figure 8.1: Regulatory Strategy for CAR T-Cell Therapy in U.S
Figure 8.2: Steps for Obtaining Marketing Authorization
Figure 8.3: USFDA Review Timeline
Figure 8.4: Regulatory Strategy for CAR T-Cell Therapy in EU
Figure 8.5: EMA Review Timeline
Figure 10.1: Global CAR T-Cell Therapy: Impact Analysis
Figure 10.2: Estimated Cases of Hematologic Malignancies in U.S., 2020
Figure 10.3: Estimated Number of Hematologic Malignancies, 2018 and 2030
Figure 10.4: Number of Clinical Trial, 2015-2020
Figure 10.5: Global CAR T-Cell Therapy Market, 2017-2019
Figure 10.6: CAR T-Cell Research Activity, 2018
Figure 11.1: Revenue Contribution of Different Segments, 2020 and 2030
Figure 11.2: Global CAR T-Cell Therapy Market (for DLBCL), 2019-2030
Figure 11.3: Global CAR T-Cell Therapy Market (for ALL), 2019-2030
Figure 11.4: Global CAR T-Cell Therapy Market (for MM), 2019-2030
Figure 11.5: Global CAR T-Cell Therapy Market (for CLL), 2019-2030
Figure 11.6: Global CAR T-Cell Therapy Market (for FL), 2019-2030
Figure 11.7: Global CAR T-Cell Therapy Market (for MCL), 2019-2030
Figure 11.8: Global CAR T-Cell Therapy Market (for Others), 2019-2030
Figure 12.1: Global CAR T-Cell Therapy Market (by Target Antigen)
Figure 12.2: Global CAR T-Cell Therapy Market (for CD19/CD22), 2019-2030
Figure 12.3: Global CAR T-Cell Therapy Market (for BCMA), 2019-2030
Figure 12.4: Global CAR T-Cell Therapy Market (for Other Antigens), 2019-2030
Figure 13.1: Global CAR T-Cell Therapy Market (by Region)
Figure 13.2: Global CAR T-Cell Therapy Market (by Region), 2019-2030
Figure 13.3: North America CAR T-Cell Therapy Market, 2019-2030
Figure 13.4: North America: Market Dynamics
Figure 13.5: Revenue Contributions of Various Countries in North America, 2019 and 2030
Figure 13.6: U.S. CAR T-Cell Therapy Market, 2019-2030
Figure 13.7: U.S. CAR T-Cell Therapy Market (by Application), 2019-2030
Figure 13.8: Canada CAR T-Cell Therapy Market, 2019-2030
Figure 13.9: Canada CAR T-Cell Therapy Market (by Application), 2019-2030
Figure 13.10: Europe CAR T-Cell Therapy Market, 2019-2030
Figure 13.11: Europe: Market Dynamics
Figure 13.12: Revenue Contributions of Various Countries in Europe, 2019 and 2030
Figure 13.13: Germany CAR T-Cell Therapy Market, 2019-2030
Figure 13.14: Germany CAR T-Cell Therapy Market (by Application), 2019-2030
Figure 13.15: U.K. CAR T-Cell Therapy Market, 2019-2030
Figure 13.16: U.K. CAR T-Cell Therapy Market (by Application), 2019-2030
Figure 13.17: France CAR T-Cell Therapy Market, 2019-2030
Figure 13.18: France CAR T-Cell Therapy Market (by Application), 2019-2030
Figure 13.19: Italy CAR T-Cell Therapy Market, 2019-2030
Figure 13.20: Italy CAR T-Cell Therapy Market (by Application), 2019-2030
Figure 13.21: Spain CAR T-Cell Therapy Market, 2019-2030
Figure 13.22: Spain CAR T-Cell Therapy Market (by Application), 2019-2030
Figure 13.23: Rest-of-Europe CAR T-Cell Therapy Market, 2019-2030
Figure 13.24: Rest-of-Europe CAR T-Cell Therapy Market (by Application), 2019-2030
Figure 13.25: Asia-Pacific CAR T-Cell Therapy Market, 2019-2030
Figure 13.26: Asia-Pacific: Market Dynamics
Figure 13.27: Revenue Contributions of Various Countries in Asia-Pacific, 2019 and 2030
Figure 13.28: Japan CAR T-Cell Therapy Market, 2019-2030
Figure 13.29: Japan CAR T-Cell Therapy Market (by Application), 2019-2030
Figure 13.30: Australia CAR T-Cell Therapy Market, 2019-2030
Figure 13.31: Australia CAR T-Cell Therapy Market (by Application), 2019-2030
Figure 13.32: Rest-of-APAC CAR T-Cell Therapy Market, 2019-2030
Figure 13.33: Rest-of-APAC CAR T-Cell Therapy Market (by Application), 2019-2030
Figure 13.34: Latin America: Market Dynamics
Figure 13.35: RoW CAR T-cell therapy market, 2019-2030
Figure 14.1: Share of Key Developments and Strategies, July 2015 - July 2020
Figure 14.2: Regulatory and Legal Developments Share (by Company), July 2015 - July 2020
Figure 14.3: Partnerships, Alliances, and Business Expansions (by Company), July 2015 - July 2020
Figure 14.4: M&A Activities Share (by Company), July 2015 - July 2020
Figure 14.5: Market Share Analysis (by Company), 2018 and 2019
Figure 15.1: Total Number of Companies Profiled
Figure 15.2: Amgen, Inc.: Overall Financials, 2017-2019
Figure 15.3: Amgen, Inc.: Sales (by Product), 2017-2019
Figure 15.4: Amgen, Inc.: Revenue (by Region), 2017-2019
Figure 15.5: Amgen, Inc.: R&D Expenditure, 2017-2019
Figure 15.6: Amgen, Inc.: SWOT Analysis
Figure 15.7: Autolus Therapeutics plc: Overall Financials, 2017-2019
Figure 15.8: Autolus Therapeutics plc: R&D Expenditure, 2017-2019
Figure 15.9: Autolus Therapeutics plc: SWOT Analysis
Figure 15.10: Bellicum Pharmaceuticals, Inc.: Overall Financials, 2017-2019
Figure 15.11: Bellicum Pharmaceuticals, Inc.: R&D Expenditure, 2017-2019
Figure 15.12: Bellicum Pharmaceuticals, Inc.: SWOT Analysis
Figure 15.13: Bluebird Bio Inc: Overall Financials, 2017-2019
Figure 15.14: Bluebird Bio Inc: R&D Expenditure, 2017-2019
Figure 15.15: Bluebird Bio Inc: SWOT Analysis
Figure 15.16: Bristol Myers Squibb Company: Overall Financials, 2017-2019
Figure 15.17: Bristol Myers Squibb Company: Revenue (by Region), 2017-2019
Figure 15.18: Bristol Myers Squibb Company: R&D Expenditure, 2017-2019
Figure 15.19: Bristol Myers Squibb Company: SWOT Analysis
Figure 15.20: CARsgen Therapeutics, Ltd.: SWOT Analysis
Figure 15.21: Cartesian Therapeutics, Inc: SWOT Analysis
Figure 15.22: Cellectis S.A.: Overall Financials, 2017-2019
Figure 15.23: Cellectis S.A.: Revenue (by Segment), 2017-2019
Figure 15.24: Cellectis S.A.: Revenue (by Region), 2017-2019
Figure 15.25: Cellectis S.A.: R&D Expenditure, 2017-2019
Figure 15.26: Cellectis S.A.: SWOT Analysis
Figure 15.27: Celyad Oncology SA: Overall Financials, 2017-2019
Figure 15.28: Celyad Oncology SA: Revenue (by Segment), 2018-2019
Figure 15.29: Celyad Oncology SA: R&D Expenditure, 2017-2019
Figure 15.30: Celyad Oncology SA: SWOT Analysis
Figure 15.31: Fortress Biotech, Inc: Overall Financials, 2017-2019
Figure 15.32: Fortress Biotech, Inc: Revenue (by Segment), 2017-2019
Figure 15.33: Fortress Biotech, Inc: R&D Expenditure, 2017-2019
Figure 15.34: Fortress Biotech, Inc: SWOT Analysis
Figure 15.35: Janssen Pharmaceuticals, Inc: Overall Financials, 2017-2019
Figure 15.36: Janssen Pharmaceuticals, Inc: Revenue (by Segment), 2017-2019
Figure 15.37: Janssen Pharmaceuticals, Inc: Revenue (by Region), 2017-2019
Figure 15.38: Janssen Pharmaceuticals, Inc: R&D Expenditure, 2017-2019
Figure 15.39: Janssen Pharmaceuticals, Inc: SWOT Analysis
Figure 15.40: Kite Pharma, Inc: Overall Product Portfolio
Figure 15.41: Kite Pharma, Inc: Overall Financials, 2017-2019
Figure 15.42: Kite Pharma, Inc: Revenue (by Segment), 2017-2019
Figure 15.43: Kite Pharma, Inc: Revenue (by Region), 2017-2019
Figure 15.44: Kite Pharma, Inc: R&D Expenditure, 2017-2019
Figure 15.45: Kite Pharma, Inc: SWOT Analysis
Figure 15.46: Legend Biotech Corporation: SWOT Analysis
Figure 15.47: Novartis AG: Overall Product Portfolio
Figure 15.48: Novartis AG: Overall Financials, 2017-2019
Figure 15.49: Novartis AG Net Revenue (by Business Segment), 2017-2019
Figure 15.50: Novartis AG: Net Revenue (by Region), 2017-2019
Figure 15.51: Novartis AG: R& D Expense, 2017-2019
Figure 15.52: Novartis AG: SWOT Analysis
Figure 15.53: Pfizer Inc.: Overall Financials, 2017-2019
Figure 15.54: Pfizer Inc.: Revenue (by Segment), 2017-2019
Figure 15.55: Pfizer Inc.: Revenue Split (by Biopharma Segment), 2017-2019
Figure 15.56: Pfizer Inc.: Revenue (by Region), 2017-2019
Figure 15.57: Pfizer Inc: R&D Expenditure, 2017-2019
Figure 15.58: Pfizer Inc.: SWOT Analysis

Product Code: BHL0987SA

"Global CAR T-Cell Therapy Market to Grow at a CAGR of 44.79% from 2020-2030."

Market Report Coverage - CAR T-Cell Therapy

Market Segmentation

Therapy Application - Diffuse large B-cell lymphoma (DLBCL), Acute lymphoblastic leukemia (ALL), Multiple myeloma (MM), Chronic lymphocytic leukemia (CLL), Follicular lymphoma (FL), Mantle cell lymphoma (MCL), and other cancers or indications

Target Antigen - CD19/CD22, BCMA (B-cell maturation antigen), and others target antigens

Regional Segmentation

North America - U.S., Canada

Europe - Germany, France, Italy, U.K., Spain, and Rest-of-Europe

Asia-Pacific - China, Japan, India, South Korea, Australia, and Rest-of-Asia-Pacific (RoAPAC)

Latin America - Brazil, Mexico, and Rest-of-the-Latin America

Rest-of-the-World

Growth Drivers

Rising Number of Patients with Hematologic Cancers

Dramatic Rise in Global CAR T-Cell Trials

Landmark Approvals of CAR T-Cell Therapies by the U.S. FDA and the EMA

Market Challenges

High Treatment Cost of CAR T-Cell Therapy

Side Effects of CAR T-Cell Therapy

Market Opportunities

Opportunities for Immunotherapy

Key Companies Profiled

Amgen, Inc., Autolus Therapeutics plc., Bellicum Pharmaceuticals, Inc., Bluebird Bio Inc., Bristol-Myer Squibb, CARsgen Therapeutics, Ltd., Cartesian Therapeutics, Inc., Cellectis S.A., Celyad Oncology SA, Fortress Biotech, Inc., Janssen Pharmaceuticals, Inc., Kite Pharma, Inc., Legend Biotech Corporation, Novartis AG, and Pfizer, Inc.

Key Questions Answered in this Report:

What is a CAR T-cell?

How are CAR T-cells developed?

What are the various indications targeted using CAR T-cell therapies?

What are the various CAR T-cell therapies available in the market?

What are the emerging CAR T-cell therapies for the treatment of hematologic cancers?

How does the pipeline for the global CAR T-cell therapy market look like?

What is the current market size and future potential of these CAR T-cell therapies?

What are the major market drivers, challenges, and opportunities in the global CAR T-cell therapy market?

What is the mechanism of action of various CAR T-cell therapies available in the market?

What mechanisms of action and molecules are being trialed the most in pipeline products?

What are the target antigens in CAR T-cell therapy?

How does the clinical trial landscape look for the global CAR T-cell therapy market?

What is the patent landscape of this market? What will be the impact of patent expiry on this market?

What is the price structure of CAR T-cell products?

What is the total cost of treating a patient with CAR T-cell therapy?

What will be the impact of COVID-19 on this market?

What are the guidelines implemented by different government bodies to regulate the approval of CAR T-cell therapy?

What are the reimbursement scenario and regulatory structure for CAR T-cell therapy?

What are the challenges faced by manufacturers in CAR T-cell therapy development?

What are the key technological developments on which the current industry leaders are spending a major share of their research and development (R&D) investments?

Which are the leading players currently holding dominating shares in the global CAR T-cell therapy market?

What are the key strategies incorporated by the players of the global CAR T-cell therapy market to sustain the competition and retain their supremacy?

What is the current revenue contribution of the global CAR T-cell therapy market (by application type), and how is it expected to evolve in the forecast period?

What is the current revenue contribution of the global CAR T-cell therapy market (by target antigen), and how is it expected to evolve in the forecast period?

Which region is expected to contribute the highest revenue to the global CAR T-cell therapy market during the forecast period?

Market Overview

The scientific community has been pursuing research for the development of CAR T-cell therapy for over a century. Immunotherapy has emerged as an innovative treatment option over decades, as it harnesses the patient's immune system to attack cancer. The global market for CAR T-cell therapy is predicted to grow at a CAGR of 44.79% over the forecast period 2020-2030. The market is driven by certain factors, which include increasing global geriatric population, increasing number of lymphoma and leukemia cases, rising number of relapsed or refractory cancer cases showing response failure to alternative treatments such as chemotherapy and radiation therapy, focus on research and development of novel immunotherapies, and strong product pipeline of global CAR T-cell therapy.

The market is favored by the development of CAR T-cell therapy for several clinical areas such as diffuse large B-cell lymphoma (DLBCL), acute lymphoblastic leukemia (ALL), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and other cancers or indications. The increase in the geriatric population and the increasing number of lymphoma and leukemia cases across the globe are expected to translate into a significantly higher demand for the CAR T-cell therapy market.

Furthermore, the companies are investing huge amounts in research and development of CAR T-cell therapy either as a monotherapy or as combination therapy. The clinical trial landscape of various hematologic cancers has been on the rise in recent years, and this will fuel the CAR T-cell therapy market in the future.

Within the research report, the market is segmented based on application, target antigen, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the application of precision medicine on a global level has created a buzz among companies to invest in the development of novel CAR T-cell therapy. Due to the diverse product portfolio and intense market penetration, Novartis AG. has been a pioneer in this field and has been a significant competitor in this market.

The pharmaceutical leading manufacturer, Kite Pharma, Inc. (a Gilead Company), has launched its CAR T-cell therapies into the market such as Yescarta (axicabtagene ciloleucel), and Tecartus (brexucabtagene autoleucel) to compete with Novartis AG's Kymriah (tisagenlecleucel) therapy market dominance.

Based on region, North America holds the largest share of the CAR T-cell therapy market due to improved healthcare infrastructure, rise in per capita income, early availability of approved therapies, and availability of state-of-the-art research laboratories and institutions in the region. Apart from this, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period.

Executive Summary

1 Technology Definition

1.1 Inclusion and Exclusion Criteria
- 1.1.1 Inclusions
- 1.1.2 Exclusions

2 Research Scope

2.1 Target Audience
2.2 Key Questions Answered in the Report

3 Research Methodology

3.1 CAR T-Cell Therapy: Research Methodology
3.2 Primary Data Sources
3.3 Secondary Data Sources
3.4 Market Estimation Model
3.5 Criteria for Company Profiling

4 Market Overview

4.1 Timeline of CAR T-Cell Therapy Development
4.2 CAR T-Cell Therapy Market and Growth Potential, 2019-2030
4.3 CAR T-Cell Therapy and Clinical Trials Landscape
- 4.3.1 Overview
- 4.3.2 Clinical Trials in China
- 4.3.3 Clinical Trials in Rest-of-the-World

5 Global CAR T-Cell Therapy Market, $Million, 2019-2030

5.1 Commercialized Therapeutics
- 5.1.1 Tisagenlecleucel (Kymriah)
- 5.1.2 Axicabtagene Ciloleucel (Yescarta)
- 5.1.3 Brexucabtagene Autoleucel (Tecartus)
5.2 Pipeline Therapeutics
- 5.2.1 BB2121 (Idecaptagene Cicleucel)
- 5.2.2 JCAR017 (Lisocabtagene Maraleucel)
- 5.2.3 KTE-C19 (Axicabtagene Ciloleucel)
- 5.2.4 CTL019 (Tisagenlecleucel)
- 5.2.5 JNJ-68284528
5.3 Impact of COVID-19 - CAR T-Cell Therapy
- 5.3.1 Impact of COVID-19 on Global CAR T-Cell Therapy Market Growth Rate
- 5.3.2 Clinical Trial Disruptions and Resumptions
- 5.3.3 COVID-19 Impact on Supply Chain of CAR T-Cell Therapy Market
- 5.3.4 Reduced Diagnosis of Cancer
- 5.3.5 Impact on Commercial Operations

6 CAR T-Cell Therapy Patent Landscape

7 Epidemiology of CAR T-Cell Therapy

7.1 Overview
7.2 CAR T-Cell Therapy Side-Effects
- 7.2.1 Cytokine Release Syndrome (CRS)
- 7.2.2 CAR T-Cell-Related Encephalopathy Syndrome (CRES)
- 7.2.3 Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
7.3 Management of CAR T-Cell Therapy Side-Effects

8 Industry Insights

8.1 Overview
8.2 Regulatory Scenario of CAR T-Cell Therapy
8.3 Legal Requirements and Frameworks in U.S.
- 8.3.1 Clinical Trial Authorization
- 8.3.2 Marketing Authorization
- 8.3.3 USFDA Guidelines for BLA Submission
- 8.3.4 Post-Authorization Regulations
8.4 Legal Requirements and Frameworks in Europe
- 8.4.1 EMA Biologics License Application Process
- 8.4.2 Centralized Procedure
- 8.4.3 Decentralized Procedure
- 8.4.4 Mutual-Recognition Procedure
- 8.4.5 National Procedure
8.5 Legal Requirements and Frameworks in Asia-Pacific
- 8.5.1 Regulation of Cell Immunotherapy in China
- 8.5.2 Legal Requirements and Frameworks in Japan
8.6 Expedited Regulatory Designations Around the World
8.7 Pricing of CAR T-Cell Therapy
8.8 Reimbursement of CAR T-Cell Therapy

9 CAR T-Cell Therapy Development and Manufacturing

9.1 Overview
9.2 Challenges in CAR T-Cell Therapy
- 9.2.1 Therapy Approval
- 9.2.2 Manufacture Quality Control
- 9.2.3 Efficacy and Quality-Adjusted Life-Year (QALY) Assessment
- 9.2.4 Safety Assessment
- 9.2.5 Pricing and Patient Access
- 9.2.6 Reimbursement

10 Market Dynamics

10.1 Impact Analysis
10.2 Market Drivers
- 10.2.1 Rising Number of Patients with Hematologic Cancers
- 10.2.2 Dramatic Rise in Global CAR T-Cell Trials
- 10.2.3 Landmark Approvals of CAR T-Cell Therapies by USFDA and EMA
10.3 Market Restraints
- 10.3.1 High Treatment Cost of CAR T-Cell Therapy
- 10.3.2 Side-Effects of CAR T-Cell Therapy
10.4 Market Opportunities
- 10.4.1 Opportunities for Immunotherapy

11 Global CAR T-Cell Therapy Market (by Application)

11.1 Overview
11.2 Diffuse Large B-Cell Lymphoma (DLBCL)
11.3 Acute Lymphoblastic Leukemia (ALL)
11.4 Multiple Myeloma (MM)
11.5 Chronic Lymphocytic Leukemia (CLL)
11.6 Follicular Lymphoma (FL)
11.7 Mantle Cell Lymphoma (MCL)
11.8 Others

12 Global CAR T-Cell Therapy Market (by Target Antigen)

12.1 Overview
12.2 CD19/CD22
12.3 BCMA (B-Cell Maturation Antigen)
12.4 Other Antigens

13 Global CAR T-Cell Therapy Market (by Region)

13.1 Introduction
13.2 North America
- 13.2.1 U.S.
  - 13.2.1.1 U.S. CAR T-Cell Therapy Market (by Application), 2019-2030
- 13.2.2 Canada
  - 13.2.2.1 Canada CAR T-Cell Therapy Market (by Application), 2019-2030
13.3 Europe
- 13.3.1 Germany
  - 13.3.1.1 Germany CAR T-Cell Therapy Market (by Application), 2019-2030
- 13.3.2 U.K.
  - 13.3.2.1 U.K. CAR T-Cell Therapy Market (by Application), 2019-2030
- 13.3.3 France
  - 13.3.3.1 France CAR T-Cell Therapy Market (by Application), 2019-2030
- 13.3.4 Italy
  - 13.3.4.1 Italy CAR T-Cell Therapy Market (by Application), 2019-2030
- 13.3.5 Spain
  - 13.3.5.1 Spain CAR T-Cell Therapy Market (by Application), 2019-2030
- 13.3.6 Rest-of-Europe
  - 13.3.6.1 Rest-of-Europe CAR T-Cell Therapy Market (by Application), 2019-2030
13.4 Asia-Pacific
- 13.4.1 China
- 13.4.2 Japan
  - 13.4.2.1 Japan CAR T-Cell Therapy Market (by Application), 2019-2030
- 13.4.3 India
- 13.4.4 South Korea
- 13.4.5 Australia
  - 13.4.5.1 Australia CAR T-Cell Therapy Market (by Application), 2019-2030
- 13.4.6 Rest-of-APAC
  - 13.4.6.1 Rest-of-APAC CAR T-Cell Therapy Market (by Application), 2019-2030
13.5 Latin America
- 13.5.1 Brazil
- 13.5.2 Mexico
- 13.5.3 Rest-of-Latin America
13.6 Rest-of-the-World

14 Competitive Landscape

14.1 Key Developments and Strategies
- 14.1.1 Overview
  - 14.1.1.1 Regulatory and Legal Developments
  - 14.1.1.2 Partnerships, Alliances, and Business Expansions
  - 14.1.1.3 M&A Activities
  - 14.1.1.4 Funding Activities
14.2 Market Share Analysis

15 Company Profiles

15.1 Overview
15.2 Amgen, Inc.
- 15.2.1 Company Overview
- 15.2.2 Role of Amgen, Inc. in Global CAR T-Cell Therapy Market
- 15.2.3 Financials
- 15.2.4 R&D Expenditure, 2017-2019
- 15.2.5 SWOT Analysis
15.3 Autolus Therapeutics plc
- 15.3.1 Company Overview
- 15.3.2 Role of Autolus Therapeutics plc in Global CAR T-Cell Therapy Market
- 15.3.3 Financials
- 15.3.4 R&D Expenditure, 2017-2019
- 15.3.5 SWOT Analysis
15.4 Bellicum Pharmaceuticals, Inc.
- 15.4.1 Company Overview
- 15.4.2 Role of Bellicum Pharmaceuticals, Inc. in Global CAR T-Cell Therapy Market
- 15.4.3 Financials
- 15.4.4 R&D Expenditure, 2017-2019
- 15.4.5 SWOT Analysis
15.5 Bluebird Bio Inc
- 15.5.1 Company Overview
- 15.5.2 Role of Bluebird Bio Inc in Global CAR T-Cell Therapy Market
- 15.5.3 Financials
- 15.5.4 R&D Expenditure, 2017-2019
- 15.5.5 SWOT Analysis
15.6 Bristol-Myers Squibb Company
- 15.6.1 Company Overview
- 15.6.2 Role of Bristol Myers Squibb Company in Global CAR T-Cell Therapy Market
- 15.6.3 Financials
- 15.6.4 R&D Expenditure, 2017-2019
- 15.6.5 SWOT Analysis
15.7 CARsgen Therapeutics, Ltd.
- 15.7.1 Company Overview
- 15.7.2 Role of CARsgen Therapeutics, Ltd. in Global CAR T-Cell Therapy Market
- 15.7.3 SWOT Analysis
15.8 Cartesian Therapeutics, Inc.
- 15.8.1 Company Overview
- 15.8.2 Role of Cartesian Therapeutics, Inc. in Global CAR T-Cell Therapy Market
- 15.8.3 SWOT Analysis
15.9 Cellectis S.A.
- 15.9.1 Company Overview
- 15.9.2 Role of Cellectis S.A. in Global CAR T-Cell Therapy Market
- 15.9.3 Financials
- 15.9.4 R&D Expenditure, 2017-2019
- 15.9.5 SWOT Analysis
15.1 Celyad Oncology SA
- 15.10.1 Company Overview
- 15.10.2 Role of Celyad Oncology SA in Global CAR T-Cell Therapy Market
- 15.10.3 Financials
- 15.10.4 R&D Expenditure, 2017-2019
- 15.10.5 SWOT Analysis
15.11 Fortress Biotech, Inc
- 15.11.1 Company Overview
- 15.11.2 Role of Fortress Biotech, Inc. in Global CAR T-Cell Therapy Market
- 15.11.3 Financials
- 15.11.4 R&D Expenditure, 2017-2019
- 15.11.5 SWOT Analysis
15.12 Janssen Pharmaceuticals, Inc.
- 15.12.1 Company Overview
- 15.12.2 Role of Janssen Pharmaceuticals, Inc in Global CAR T-Cell Therapy Market
- 15.12.3 Financials
- 15.12.4 R&D Expenditure, 2017-2019
- 15.12.5 SWOT Analysis
15.13 Kite Pharma, Inc (A Gilead Company)
- 15.13.1 Company Overview
- 15.13.2 Role of Kite Pharma, Inc in Global CAR T-Cell Therapy Market
- 15.13.3 Financials
- 15.13.4 R&D Expenditure, 2017-2019
- 15.13.5 SWOT Analysis
15.14 Legend Biotech Corporation
- 15.14.1 Company Overview
- 15.14.2 Role of Legend Biotech Corporation. in Global CAR T-Cell Therapy Market
- 15.14.3 SWOT Analysis
15.15 Novartis AG
- 15.15.1 Company Overview
- 15.15.2 Role of Novartis AG in Global CAR T-Cell Therapy Market
- 15.15.3 Financials
- 15.15.4 R&D Expenditure, 2017-2019
- 15.15.5 SWOT Analysis
15.16 Pfizer Inc.
- 15.16.1 Company Overview
- 15.16.2 Role of Pfizer Inc. in Global CAR T-Cell Therapy Market
- 15.16.3 Financials
- 15.16.4 R&D Expenditure, 2017-2019
- 15.16.5 SWOT Analysis